Drug Profile
Sepetaprost - Santen Pharmaceutical
Alternative Names: DE 126; ONO 9054; STN-10126; STN-1012600Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ono Pharmaceutical
- Developer Ono Pharmaceutical; Santen Pharmaceutical
- Class Antiglaucomas; Oxepins; Prostaglandins
- Mechanism of Action Prostaglandin E EP3 receptor agonists; Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Ocular hypertension; Open-angle glaucoma
Most Recent Events
- 21 Jun 2023 Company completes a phase I pharmacokinetic trial (In volunteers, In adults) in Japan (Ophthalmic) (NCT05905653)
- 25 May 2023 Santen Pharmaceutical initiates a phase I pharmacokinetic trial (In volunteers, In adults) in Japan (Ophthalmic) (NCT05905653)
- 18 Apr 2023 Santen Pharmaceutical completes a phase III trial for Open-angle glaucoma in Japan (Ophthalmic) (NCT05495061)